Hong Kong Shares End Week in Red; Sunho Biologics Gains in Debut
Hong Kong Shares End Week in Red; Sunho Biologics Gains in Debut
Akeso's (HKG:9926) shares slumped nearly 23% at closing despite receiving marketing approval in China for its non-small cell lung cancer drug IVONESCIMAB. Hong Kong stocks finished lower on Friday, extending losses seen in previous sessions this week, as rate cut worries continue to dampen investor sentiment.
由于降息担忧继续抑制投资者情绪，香港股市周五收低，延续了本周前几个交易日的跌势。
The Hang Seng Index declined 1.38%, or 259.77 points, to close at 18,608.94. The Hang Seng China Enterprises Index fell 1.44%, or 96.54 points, to 6,605.24.
恒生指数下跌1.38％，跌幅259.77点，收于18,608.94点。恒生中国企业指数下跌1.44％，或96.54点，至6,605.24点。
In corporate news, Sunho Biologics (HKG:2898) made a strong trading debut in Hong Kong on Friday. The clinical-stage biotech firm closed at HK$14.52 per share, up by almost 8% from its IPO price of HK$13.50.
在企业新闻方面，三和生物制药（HKG: 2898）周五在香港首次亮相，表现强劲。这家处于临床阶段的生物技术公司收于每股14.52港元，较其13.50港元的首次公开募股价格上涨了近8％。
Akeso's (HKG:9926) shares slumped nearly 23% at closing despite receiving marketing approval in China for its non-small cell lung cancer drug IVONESCIMAB.
尽管其非小细胞肺癌药物IVONESCIMAB在中国获得了上市许可，但Akeso（HKG: 9926）的股价在收盘时仍下跌了近23％。
Hong Kong-listed shares of China Vanke (HKG:2202, SHE:000002) dropped 9% after the real estate developer said it borrowed 20 billion yuan through a syndicated loan facility.
中国万科（HKG: 2202，SHE: 000002）在香港上市的股票下跌了9％，此前该房地产开发商表示通过银团贷款机制借入了200亿元人民币。
